FDA approves video game for treating ADHD in kids

  • FILE - In this Aug. 2, 2018, file photo, the U.S. Food and Drug Administration (FDA) building is visible behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md. The U.S. Food and Drug Administration has for the first time approved a video game for treating attention deficit hyperactivity disorder in children. The FDA said Monday, June 15, 2020, the game built by Boston-based Akili Interactive Labs can improve attention function.

    FILE - In this Aug. 2, 2018, file photo, the U.S. Food and Drug Administration (FDA) building is visible behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md. The U.S. Food and Drug Administration has for the first time approved a video game for treating attention deficit hyperactivity disorder in children. The FDA said Monday, June 15, 2020, the game built by Boston-based Akili Interactive Labs can improve attention function. Associated Press

 
 
Updated 6/16/2020 12:34 AM

BOSTON -- The U.S. Food and Drug Administration has for the first time approved a video game for treating attention deficit hyperactivity disorder in children.

The FDA said Monday the game built by Boston-based Akili Interactive Labs can improve attention function.

                                                                                                                                                                                                                       
 

The game, called EndeavorRx, requires a prescription and is designed for children ages 8 to 12 with certain symptoms of ADHD.

It's the first time the FDA has cleared a digital therapy for improving ADHD symptoms, and the first time the agency has ever authorized marketing of a game-based therapy for any condition.

The FDA says it looked at data from multiple studies in more than 600 children. A video of the game shows a character traveling a racecourse-like path in a hover board. Sensory and motor tasks are designed to help the player improve cognitive functioning.

'We're proud to make history today with FDA's decision,' Akili CEO Eddie Martucci said in a statement. 'We're using technology to help treat a condition in an entirely new way as we directly target neurological function through medicine that feels like entertainment."

0 Comments
                                                                                                                                                                                                                       
 
Article Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.